NCT06878859 Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use
| NCT ID | NCT06878859 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts General Hospital |
| Condition | Depression - Major Depressive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-02-23 |
| Primary Completion | 2028-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2026-02-23 with a primary completion date of 2028-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings.
Eligibility Criteria
Inclusion Criteria: * Aged ≥ 18 years * Resides in the United States * Able to read and understand English and willing to provide informed consent/comply with the study protocol * Moderate depressive symptom severity, as indicated by the Patient Health Questionnaire-9 (PHQ-9) * Problematic cannabis use, as indicated by the Cannabis Use Disorder Identification Test - Revised (CUDIT-R) * Current elevated anhedonia, as indicated by the PHQ-9 * Interest in receiving treatment for their cannabis use and depression * Meet criteria for current MDD and CUD per the DSM-5 Exclusion Criteria: * History of a psychotic disorder or bipolar disorder type I/II * Active suicidal ideation or intent based on the Columbia-Suicide Severity Rating Scale * Current psychotherapy engagement * Changes in psychotropic medication within six weeks of the start of study
Frequently Asked Questions
Who can join the NCT06878859 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Depression - Major Depressive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06878859 currently recruiting?
Yes, NCT06878859 is actively recruiting participants. Visit ClinicalTrials.gov or contact Massachusetts General Hospital to inquire about joining.
Where is the NCT06878859 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06878859 clinical trial?
NCT06878859 is sponsored by Massachusetts General Hospital. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.